Synthesis and evaluation of 1,2,3-triazole containing analogues of the immunostimulant α-GalCer

Journal of Medicinal Chemistry

Volumn 50, Issue 3, 2007, Pages 585-589

  Lee, Taeho ^a   Cho, Minjae ^a   Ko, Sung Youl ^a   Youn, Hyun Jun ^a   Dong, Jae Baek ^a   Cho, Won Jea ^b   Kang, Chang Yuil ^a   Kim, Sanghee ^a  

^a Seoul National University   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3 TRIAZOLE DERIVATIVE; ALPHA GALACTOSYLCERAMIDE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR;

ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IMMUNOSTIMULATION; NATURAL KILLER T CELL; STRUCTURE ACTIVITY RELATION; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD1; CELL LINE, TUMOR; COCULTURE TECHNIQUES; GALACTOSYLCERAMIDES; HUMANS; HYBRIDOMAS; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; RATS; RECEPTORS, ANTIGEN, T-CELL; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; TH2 CELLS; TRIAZOLES;

EID: 33846916151     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061243q     Document Type: Article

References (31)

1. Brigl, M.; Brenner, M. B. CD1: Antigen presentation and T cell function. Annu. Rev. Immunol. 2004, 22, 817-890.
2. For recent reviews of the biology of NKT cells, see: (a) Kronenberg, M. Toward an understanding of NKT cell biology: Progress and paradoxes. Annu. Rev. Immunol. 2005, 23, 877-900.
3. (b) Van Kaer, L. α-Galactosylceramide therapy for autoimmune diseasies: prospects and obstacles. Nat. Rev. Immunol. 2005, 5, 31-42.
4. Morita, M.; Motoki, K.; Akimoto, K.; Natori, T.; Sakai, T.; Sawa, E.; Yamaji, K.; Koezuka, Y.; Kobayashi, E.; Fukushima, H. Structure-activity relationship of α-galactosylceramides against B16-bearing mice. J. Med. Chem. 1995, 38, 2176-2187.
5. Godfrey, D. I.; Hammond, K. J. L.; Poulton, L. D.; Smyth, M. J.; Baxter, A. G. NKT cells: Facts, function and fallacies. Immunol. Today 2000, 21, 573-583.
6. For recent reviews, see: (a) Savage, P. B.; Teyton, L.; Bendelac, A. Glycolipids for natural killer T cells. Chem. Soc. Rev. 2006, 35, 771-779.
7. (b) Tsuji, M. Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands. Cell. Mol. Life Sci. 2006, 63, 1889-1898.
8. (c) Yamamura, T.; Miyamoto, K.; Illés, Z.; Pál, E.; Araki, M.; Miyake, S. NKT cell-stimulating synthetic glycolipids as potential therapeutics for antoimmune disease. Curr. Top. Med. Chem. 2004, 4, 561-567.
9. α-14 NKT cells by glycosylceramides. Science 1997, 278, 1626-1629.
10. Brossay, L.; Naidenko, O.; Burdin, N.; Matsuda, J.; Sakai, T.; Kronenberg, M. Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells. J. Immunol. 1998, 161, 5124-5128.
11. (a) Barbieri, L.; Costantino, V.; Fattorusso, E.; Mangoni, A.; Aru, E.; Parapini, S.; Taramelli, D. Immunomodulatory α-galactoglycosphingolipids: Synthesis of 2′-O-methyl-α-Gal-GSL and evaluation of its immunstimulating capacity. Eur. J. Org. Chem. 2004, 468-473.
12. (b) Barbieri, L.; Costantino, V.; Fattorusso, E.; Mangoni, A.; Basilico, N.; Mondani, M.; Taramelli, D. Immunomodulatory α- galactoglycosphingolipids: synthesis of 2′-fluoro-2′-deoxy-α- galactosylceramide and an evaluation of its immunostimulating properties. Eur. J. Org. Chem. 2005, 3279-3285.
13. Xing, G.-W.; Wu, D.; Poles, M. A.; Horowitz, A.; Tsuji, M.; Ho, D. D.; Wong, C.-H. Synthesis and human NKT cell stimulating properties of 3-O-sulfo-α/β-galactosylceramides. Bioorg. Med. Chem. 2005, 13, 2907-2916.
14. Wu, D.; Xing, G.-W.; Poles, M. A.; Horowitz, A.; Kinjo, Y.; Sullivan, B.; Bodmer-Narkevitch, V.; Plettenburg, O.; Kronenberg, M.; Tsuji, M.; Ho, D. D.; Wong, C.-H. Bacterial glycolipids and analogs as antigens for CD Id-restricted NKT cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 1351-1356.
15. Zhou, X.-T.; Forestier, C.; Goff, R. D.; Li, C.; Teyton, L.; Bendelac, A.; Savage, P. B. Synthesis and NKT cell stiumlating properties of fluorophore- and biotin-appended 6″-amino-6″-deoxy-galactosylceramides. Org. Lett. 2002, 4, 1267-1270.
16. Goff, R. D.; Gao, Y.; Mattner, J.; Zhou, D.; Yin, N.; Cantu, C., III; Teyton, L.; Bendelac, A.; Savage, P. B. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J. Am. Chem. Soc. 2004, 126, 13602-13603.
17. H2 bias of natural killer T cells. Nature 2001, 413, 531-534.
18. Fujio, M.; Wu, D.; Garcia-Navarro, R.; Ho, D. D.; Tsuji, M.; Wong, C.-H. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: Tuning the adjuvant versus immunosuppression activity. J. Am. Chem. Soc. 2006, 128, 9022-9023.
19. For review, see: Franck, R. W.; Tsuji, M. α-C- Galactosylceramides: Synthesis and immunology. Acc. Chem. Res. 2006, 39, 692-701.
20. Zajonc, D. M.; Cantu, C., III; Mattner, J.; Zhou, D.; Savage, P. B.; Bendelac, A.; Wilson, I. A.; Teyton, L. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat. Immunol. 2005, 6, 810-818.
21. Koch, M.; Stronge, V. S.; Shepherd, D.; Gadola, S. D.; Mathew, B.; Ritter, G.; Fersht, A. R.; Besra, G. S.; Schmidt, R. R.; Jones, E. Y.; Cerundolo, V. The crystal structure of human CD1d with and without α-galactosylceramide. Nat. Immunol. 2005, 6, 819-826.
22. For recent reviews on 1,2,3-triazoles, see: (a) Kolb, H. C.; Sharpless, K. B. The growing impact of click chemistry on drug discovery. Drug Discovery Today 2003, 8, 1128-1137.
23. (b) Wang, Q.; Chittaboina, S.; Barnhill, H. N. Advances in 1,3-dipolar cycloaddition reaction of azides and alkynes - a prototype of "Click" chemistry. Lett. Org. Chem. 2005, 2, 293-301.
24. I-catalyzed alkyne-azide "Click" cycloaddtions from a mechanistic and synthetic perspective. Eur. J. Org. Chem. 2006, 51-68.
25. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click chemistry: Diverse chemical function from a few good reactions. Angew. Chem., Int. Ed. 2001, 40, 2004-2021.
26. Du, W.; Gervay-Hague, J. Efficient synthesis of α-galactosyl ceramide analogues using glycosyl iodide donors. Org. Lett. 2005, 7, 2063-2065.
27. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A stepwise Huisgen cycloaddtion process: Copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem., Int. Ed. 2002, 41, 2596-2599.
28. Zhou, D.; Mattner, J.; Cantu, C., III; Schrantz, N.; Yin, N.; Gao, Y.; Sagiv, Y.; Hudspeth, K.; Wu, Y.-P.; Yamashita, T.; Teneberg, S.; Wang, D.; Proia, R. L.; Levery, S. B.; Savage, P. B.; Teyton, L.; Bendelac, A. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004, 306, 1786-1789.
29. α14 NK T cells. J. Immunol. 2001, 166, 662-668.
30. Fujii, S.-i.; Shimizu, K.; Kronenberg, M.; Steinman, R. M. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat. Immunol. 2002, 3, 867-874.
31. - T cells in mice and humans. J. Exp. Med. 1994, 180, 1097-1106.